| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.038 | 0.5 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | -0.039 | 0.5 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | 0.1 | 0.5 |
| mRNA | selumetinib:UNC0638 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.027 | 0.5 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.046 | 0.5 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.5 |